Slides
Page 1
Investor Presentation July 2026 Trusted. Tested. Transforming. CARE THAT MOVES FORWARD, EVERY YEAR. Investor Presentation: October 2026 (Q2 & H1FY27)
Page 2
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Jupiter Life Line Hospitals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. 2
Page 3
Management Commentary Dr. Ankit Thakker MD & CEO P a t i e n t F i r s t 3 “I am pleased to share that, following successful negotiations with the landowner, the Board has approved the acquisition of the land currently leased for our Pune South hospital. The land measures 11,452.07 sq. m. and the total consideration is Rs 150 cr. The Rs 50 cr deposit paid earlier will be adjusted against this, so the incremental cash outflow is limited to Rs 100 cr. Owning the land removes long-term lease risk and strengthens our asset base at one of our key growth locations. Construction at Pune South is progressing well and remains on schedule. The Mira Road and BKC projects are currently in the regulatory approval and planning stages. Our Dombivli hospital saw a higher infectious-disease burden this quarter, which drove higher occupancy compared with the previous quarter. This helped narrow its EBITDA loss to Rs 0.2 cr for the period. Our other three hospitals continued to perform in line with expectations.”
Page 4
Q2FY27 Performance Highlights 4 57.4 37.5 56.4 Q2FY26 Q1FY27 Q2FY27 67.0 72.6 77.8 309.8 320.0 358.5 16.8 Q2FY26 18.4 Q1FY27 20.2 Q2FY27 393.6 411.0 456.5 74.2 50.6 75.1 Q2FY26 Q1FY27 Q2FY27 92.2 79.3 106.9 Q2FY26 Q1FY27 Q2FY27 Rs in Cr Total Income EBITDA PBT PAT • EBITDA impact on account of the new Dombivli hospital was only Rs. 0.2 cr (due to higher medical admissions) in Q2FY27 vs Rs. 9.5 cr in Q1FY27. IPD OPD Others
Page 5
H1FY27 Performance Highlights 5 101.4 93.9 H1FY26 H1FY27 130.1 150.3 584.6 678.5 31.9 H1FY26 38.7 H1FY27 746.6 867.5 IPD OPD Others 136.0 125.7 H1FY26 H1FY27 170.7 186.2 H1FY26 H1FY27 Rs in Cr Total Income EBITDA PBT PAT • EBITDA impacted by initial ramp-up losses at Dombivli Hospital of Rs. 9.7 cr in H1FY27 along with higher marketing costs related to launch activities • Higher depreciation following commercialisation of Dombivli hospital • Higher finance costs owing to an increase debt drawdown for ongoing capex
Page 6
H1FY27 Operating Metrics 6 196 929 1,063 132 H1FY26 H1FY27 1,061 1,259 62.2% 59.5% H1FY26 H1FY27 66,100 71,800 H1FY26 H1FY27 3.84 3.79 H1FY26 H1FY27 511.5 584.1 27.4 H1FY26 30.4 H1FY27 IPD OPD 538.9 614.5 55.5% 54.8% 43.2% 44.2% 1.3% H1FY26 1.0% H1FY27 Government Schemes Self Payors Insurance Companies Census Beds Non - Census Beds Operational Bed Capacity(1) Average Occupancy Rate(2) IPD & OPD Volumes (‘000)(3) ARPOB(4) ALOS (in Days)(6) Payor Mix ARPOB and IP ARPOB rounded off to the nearest hundred 1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units (“ICUs”), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out- patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) Calculated on Inpatient Revenue divided by Inpatient occupied bed days (excluding daycare) (6) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume. 64.8% Excluding Dombivli Hospital 53,800 58,700 H1FY26 H1FY27 IP ARPOB (5)
Page 7
Consolidated Profit & Loss Statement 7 • EBITDA includes an operational loss from Dombivli Hospital for Rs 0.2 cr and Rs 9.5 cr for Q2FY27 and Q1FY27 respectively and Rs 9.7 cr in H1FY27 during the initial ramp-up phase • Depreciation has increased due to capitalisation of newly added beds • Higher finance costs owing to an increase debt drawdown for ongoing capex *Statutory impact of New Labour codes Particulars (in Rs. Crs) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY FY26 Revenue from Operations 436.3 376.8 15.8% 392.6 11.1% 828.8 714.7 16.0% 1,435.6 Other Income - Operational 20.2 16.8 18.4 38.7 31.9 64.2 Total Income 456.5 393.6 16.0% 411.0 11.1% 867.5 746.6 16.2% 1,499.8 Cost of Goods Sold 86.5 73.8 80.0 166.5 144.5 287.3 Gross Profit 370.0 319.8 15.7% 331.0 11.8% 701.0 602.1 16.4% 1,212.5 Gross Profit Margin 81.1% 81.3% 80.5% 80.8% 80.6% 80.8% Employee Cost 81.3 63.2 74.5 155.8 125.0 256.3 Professional Fees 110.2 103.0 102.2 212.4 185.7 364.0 Other Expenses 71.6 61.4 75.0 146.6 120.8 248.9 EBITDA 106.9 92.2 15.9% 79.3 34.8% 186.2 170.7 9.1% 343.3 EBITDA Margin 23.4% 23.4% 19.3% 21.5% 22.9% 22.9% Depreciation 28.5 21.5 26.4 54.9 42.7 87.6 EBIT 78.4 70.7 10.9% 52.9 48.2% 131.3 128.0 2.6% 255.6 EBIT Margin 17.2% 18.0% 12.9% 15.1% 17.1% 17.0% Other Income - Finance 10.5 11.3 10.6 21.1 24.1 42.4 Finance Cost 13.8 7.8 12.9 26.7 16.1 32.7 Exceptional Item Gain / (Loss)* 0.0 0.0 0.0 0.0 0.0 4.9 PBT 75.1 74.2 1.2% 50.6 48.4% 125.7 136.0 -7.6% 260.4 PBT Margin 16.5% 18.9% 12.3% 14.5% 18.2% 17.4% Tax 18.7 16.8 13.1 31.8 34.6 66.2 PAT 56.4 57.4 -1.7% 37.5 50.4% 93.9 101.4 -7.4% 194.2 PAT Margin 12.4% 14.6% 9.1% 10.8% 13.6% 12.9% Basic EPS** 1.72 1.75 1.14 2.86 3.09 5.92 ** EPS restated pursuant to share sub-division
Page 8
Consolidated Balance Sheet 8 Equity & Liabilities (in Rs. Crs) Sep-26 Mar-26 Total Equity 1,630.5 1,544.1 Share Capital 65.6 65.6 Other Equity 1,564.7 1,478.5 Non-Controlling interest 0.2 0.0 Non-Current Liabilities 683.3 612.5 Financial Liabilities Borrowings 565.5 500.9 Lease liabilities 68.9 65.5 Provisions 17.9 16.5 Deferred Tax Liabilities 31.0 29.6 Current Liabilities 246.3 226.5 Financial Liabilities Borrowings 23.3 7.6 Lease liabilities 10.9 10.2 Trade Payables 65.1 95.5 Other financial Liabilities 96.3 70.9 Other Current Liabilities 31.9 29.7 Current tax liabilities (net) 4.0 3.4 Provisions 14.8 9.2 Total Equity & Liabilities 2,560.1 2,383.1 Assets (in Rs. Crs) Sep-26 Mar-26 Non - Current Assets 1,945.4 1,698.2 Property Plant & Equipments 1,320.7 1,276.8 Right of use assets 103.7 99.1 CWIP 193.8 129.2 Goodwill 5.1 0.0 Other Intangible assets 9.4 8.0 Financial Assets Investments 0.1 0.1 Other Financial Assets 34.6 33.2 Deferred tax assets (net) 19.5 19.8 Other Non - Current Assets (Net) 258.5 132.0 Current Assets 614.7 684.9 Inventories 35.8 38.3 Financial Assets Investments 384.7 485.7 Trade receivables 118.3 75.5 Cash and cash equivalents 45.1 54.8 Bank balances other than above 1.7 3.4 Other financial assets 0.2 6.5 Current tax assets (net) 9.7 6.5 Other Current Assets 19.2 14.2 Total Assets 2,560.1 2,383.1
Page 9
Consolidated Cash Flow Statement 9 Particulars (in Rs. Crs) H1FY27 H1FY26 Net Profit Before Tax 125.6 136.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 65.4 41.6 Operating profit before working capital changes 191.0 177.6 Changes in working capital -22.6 -13.6 Cash generated from Operations 168.4 164.0 Direct taxes paid (net of refund) -32.3 -33.8 Net Cash from Operating Activities 136.1 130.2 Net Cash from Investing Activities -176.3 -173.2 Net Cash from Financing Activities 28.4 -23.3 Net Decrease in Cash and Cash equivalents -11.8 -66.3 Add: Cash & Cash equivalents at the beginning of the period 56.9 92.5 Cash & Cash equivalents at the end of the period 45.1 26.2
Page 10
Next-Phase of Growth: Scaling Bed Capacity from 1,700 to 2,900 Strategic Priorities Behind Expansion ✓ Strategic land bank in high-demand micro markets ✓ Phased commissioning to optimize capital deployment ✓ Strong operating leverage from consolidated scale Strong post IPO Expansion of ~1,700 beds at an Average Cost/Bed of ~ Rs 1.5 Cr* Hospitals Bed Capacity Capex/Bed (Excl. Land) (Rs in cr) Expected to be operational Remarks Recently Commissioned Dombivli 500 Phase-wise commissioning underway, with ~200 beds operational and fit-outs completed for an additional 100 beds Greenfield Pune II 500 1.2 CY28 Under construction Mira - Bhayandar 300 1.3 CY29 Project currently at conceptualization and planning stage BKC 400 1.5 CY31 Documentation & registration *Including land cost 10
Page 11
Thank You Jupiter Life Line Hospitals Limited CIN: L85100MH2002PLC137908 investor.relations@jupiterhospital.com Strategic Growth Advisors Pvt. Ltd. http://www.sgapl.net/images/sgapl_logo.jpg CIN: U74140MH2010PTC204285 Mandar Chavan / Rahul Agarwal mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net +91 96993 82195 / +91 98214 38864 Jupiter Life Line Hospitals Limited CIN: L85100MH2002PLC137908 investor.relations@jupiterhospital.com